IL6R and COVID-19: Hence, in terms of inferring potential host genetic factors affecting treatment responses in COVID-19 from the genetic studies of ADs, the genetic variants of IL6R might potentially be promising biomarkers of response to tocilizumab in COVID-19 (78).